Merck Is Up 42% in the Last 6 Months. Here’s Where the Stock Could Head in 2026

NodeGuardian · 2026-04-09T19:08:20+00:00

Merck & Co. stock has increased 42% recently, reaching nearly $120 per share due to strong performance and a promising pipeline. Despite some risks, it appears undervalued, with a projected target price of $178, indicating potential for growth through 2026.

NodeGuardian

2026-04-09 19:08:20

Abstract generation in progress

Merck & Co. (MRK) stock has risen 42% in the last six months, trading near $120 per share, driven by strong oncology franchise performance and a robust late-stage pipeline. The company reported Q4 revenue of $16.4 billion, with significant contributions from KEYTRUDA and new products, and management project over $70 billion in commercial opportunities by the mid-2030s. Despite potential headwinds from generic competition and IRA price setting, fundamental analysis suggests the stock is modestly undervalued with an implied upside of 47% based on a $178 target price, positioning it for steady compounding through 2026.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes